IDEXX (IDXX) Surpasses Expectations with $902 Million in Q4 Revenue and a 13% EPS Increase

IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, reported a strong performance in the fourth quarter of 2023, underlining its continued growth and operational excellence.

IDEXX Laboratories announced a revenue of $901.6 million for the fourth quarter of 2023, marking a 9% increase compared to the same period in the previous year. This growth was driven primarily by a 10% rise in Companion Animal Group (“CAG”) Diagnostics recurring revenue, supported by high-quality placements of CAG Diagnostics capital instruments, strong customer retention, new business gains, and net price realization.

Earnings per share (EPS) for the quarter were $2.32, up 13% from the prior year, reflecting the company’s operational efficiency and strategic investments in growth. The strong quarter was further highlighted by a 10% organic growth in CAG Diagnostics recurring revenue, emphasizing IDEXX’s ability to expand its market presence and leverage its innovative diagnostic solutions.

IDEXX Labs Outperforms in Q4 with $2.32 EPS

The company’s fourth-quarter performance exceeded market expectations, with analysts projecting an EPS of $2.12 and revenue of $891.08 million. The actual revenue of $902 million and EPS of $2.32 not only surpassed these projections but also showcased IDEXX’s robust growth trajectory and ability to outperform in a competitive landscape. This outperformance is a testament to IDEXX’s strategic initiatives and its focus on delivering comprehensive pet healthcare solutions.

Join our Telegram group and never miss a breaking digital asset story.

Guidance for the Future

For 2024, IDEXX has set a revenue guidance range of $3,930 million to $4,040 million, reflecting an anticipated growth of 7.5% to 10.5%. This outlook is supported by expected CAG Diagnostics recurring revenue growth of 7.5% to 10.5%, both reported and on an organic basis. The EPS guidance for 2024 is set at $10.84 to $11.33, indicating an 8% to 13% increase. This guidance underscores the company’s confidence in its growth drivers and its commitment to sustaining momentum through innovations, such as the launch of the new slide-free cellular analyzer, IDEXX inVue Dx™, targeted for late 2024.

Disclaimer: The author does not hold or have a position in any securities discussed in the article.